Faes Farma SA
MAD:FAE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shenzhen Maxonic Automation Control Co Ltd
SZSE:300112
|
CN |
|
Z
|
Zhengzhou J&T Hi-Tech Co Ltd
SZSE:300845
|
CN |
|
N
|
Noah Holdings Ltd
HKEX:6686
|
CN |
|
F
|
FDG Electric Vehicles Ltd
HKEX:729
|
HK |
|
C
|
China Art Financial Holdings Ltd
HKEX:1572
|
CN |
|
X
|
Xali Gold Corp
OTC:CGDXF
|
CA |
|
R
|
REPT BATTERO Energy Co Ltd
HKEX:666
|
CN |
|
E
|
Enaex SA
SGO:ENAEX
|
CL |
|
T
|
Tianjin Ruixin Technology Co Ltd
SZSE:300828
|
CN |
|
N
|
Northern Region Cement Company SJSC
SAU:3004
|
SA |
|
B
|
Bergenbio ASA
OSE:BGBIO
|
NO |
|
E
|
Eureka Acquisition Corp
NASDAQ:EURK
|
CN |
|
K
|
Kuchai Development Bhd
KLSE:KUCHAI
|
MY |
|
Oncopeptides AB
STO:ONCO
|
SE |
|
F
|
Fukui Computer Holdings Inc
TSE:9790
|
JP |
Faes Farma SA
EPS (Diluted)
Faes Farma SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Faes Farma SA
MAD:FAE
|
EPS (Diluted)
€0
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Almirall SA
MAD:ALM
|
EPS (Diluted)
€0
|
CAGR 3-Years
122%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
EPS (Diluted)
€2
|
CAGR 3-Years
-10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
EPS (Diluted)
€0
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.
See Also
What is Faes Farma SA's EPS (Diluted)?
EPS (Diluted)
0.3
EUR
Based on the financial report for Dec 31, 2025, Faes Farma SA's EPS (Diluted) amounts to 0.3 EUR.
What is Faes Farma SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
10%
Over the last year, the EPS (Diluted) growth was -31%. The average annual EPS (Diluted) growth rates for Faes Farma SA have been -4% over the past three years , 2% over the past five years , and 10% over the past ten years .